Adherence is a complex behavioral process strongly influenced by environmental factors. Six posters designed to improve medication adherence were displayed in a medical clinic, with each poster displayed for 1 month. These posters were seen by clinic patients but, as passive measures, required no additional time on the part of clinicians. Medication adherence to antidepressant therapy was assessed for two 18-month periods. Days of therapy and median gap (the number of days a patient goes without medication before filling the next prescription) were similar between the periods. Medication possession ratio (MPR) was increased in the intervention period (0.974 vs 0.994 days). During the 6-month period that the adherence posters were displayed, persistence decreased by only 10% (versus 22% for the nonintervention period). Use of passive measures may improve patient medication adherence. In this prospective study, both the MPR and persistence were improved. (Drug Benefit Trends. 2008:20:17-24)
Drug Benefit Trends
Use of the antibiotic rifapentine was found to significantly shorten duration of treatment for tuberculosis (TB) in an animal study led by Eric L. Nuermberger, MD, assistant professor, Center for Tuberculosis Research at Johns Hopkins University School of Medicine, Baltimore. The study, published online December 17 in PLoS Medicine, was funded by the National Institute of Allergy and Infectious Diseases.
Premenopausal women with major depressive disorder (MDD) have less bone mineral density (BMD) than those without MDD, according to findings of a study published in the November 26 issue of Archives of Internal Medicine. Researchers reported that the level of bone loss in premenopausal women with MDD was at least as high as that associated with recognized risk factors for osteoporosis. The study was funded by the National Institute of Mental Health, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Center for Complementary and Alternative Medicine, and the Warren Magnuson Clinical Center of the NIH.
Oral Contraceptives: Five Vignettes Illustrate Dx and Rx Problems-- and Solutions
Phenytoin is one of the most commonly prescribed antiepileptic drugs in both acute and chronic settings; its use has been extensively described. Nevertheless, interactions between phenytoin and numerous other drugs continue to complicate seizure therapy; these have been documented in case reports, studies, textbooks, and epilepsy reviews.
The potential for ocular side effects in patients taking selective phosphodiesterase (PDE) 5 inhibitors has been documented.
Elderly patients who take many medications often have difficulty in remembering them all.
recently became available for the
treatment of high LDL cholesterol
levels, as adjunctive therapy to dietary
modification, in patients with
primary hypercholesterolemia or
mixed hyperlipidemia. This drug,
from Merck/Schering-Plough Pharmaceuticals,
inhibits the production
of cholesterol in the liver and blocks
the absorption of cholesterol in the
GI tract, including cholesterol obtained
Nitazoxanide (Alinia), from Romark
Laboratories, has been approved
by the FDA for the treatment of
children who have diarrhea caused
by protozoa. This agent targets
Cryptosporidium parvum and
Pitfalls in Prescribing: Macrolide-Drug Interactions: Update on the Most Common and Clinically Significant
Macrolides are commonly
used to treat a
variety of infections.
long been recognized
as having numerous highly important
drug interactions.1 Although
clarithromycin generally has somewhat
less of an effect on the clearance
of other drugs, it also has several
clinically relevant interactions.1-3